<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>药融圈 | wechat-feeds</title><link>http://MzUyNTgyNjUzMw.favicon.privacyhide.com/favicon.ico</link><description>药融圈PHARNEX汇聚数万医药大咖，得到数千家医药创业者鼎力支持，开展日常专题讲座。致力于成为“专业、前沿、权威、严谨”的医药行业资讯平台，以及项目、技术、工厂、融资、股权投资等资源整合平台。欢迎您关注药融圈，共同碰撞“药”的火花!</description><managingEditor> (hellodword)</managingEditor><pubDate>Fri, 26 Feb 2021 11:56:14 +0800</pubDate><image><url>http://MzUyNTgyNjUzMw.favicon.privacyhide.com/favicon.ico</url><title>药融圈 | wechat-feeds</title><link>http://MzUyNTgyNjUzMw.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>2020年中日药企Top10研发投入大PK—以恒瑞和武田为例</title><link>https://mp.weixin.qq.com/s/I9Z9HR2ZbVpaSaZq9Srr_g</link><description></description><content:encoded><![CDATA[2020年中日药企Top10研发投入大PK—以恒瑞和武田为例]]></content:encoded><pubDate>Thu, 25 Feb 2021 17:56:17 +0800</pubDate></item><item><title>42家国内重点创新药企最新在研管线汇总，快来get！</title><link>https://mp.weixin.qq.com/s/7Ye6HwjOgxssQYzZguSYGQ</link><description></description><content:encoded><![CDATA[42家国内重点创新药企最新在研管线汇总，快来get！]]></content:encoded><pubDate>Thu, 25 Feb 2021 17:56:17 +0800</pubDate></item><item><title>限免：大湾区生物医药创新者峰会参会报名破900</title><link>https://mp.weixin.qq.com/s/ijJ0szr_c-OZjgGo6b9i-A</link><description></description><content:encoded><![CDATA[限免：大湾区生物医药创新者峰会参会报名破900]]></content:encoded><pubDate>Thu, 25 Feb 2021 17:56:17 +0800</pubDate></item><item><title>Beam Therapeutics宣布1.2亿美元预付款收购Guide Therapeutics</title><link>https://mp.weixin.qq.com/s/GTpZ7zkagpTTEeSmiO1aMg</link><description></description><content:encoded><![CDATA[Beam Therapeutics宣布1.2亿美元预付款收购Guide Therapeutics]]></content:encoded><pubDate>Thu, 25 Feb 2021 17:56:17 +0800</pubDate></item><item><title>恒瑞榜首！A股上市药企研发投入Top100来了！</title><link>https://mp.weixin.qq.com/s/LgoPeMKm-D-xIsCers1Opg</link><description></description><content:encoded><![CDATA[恒瑞榜首！A股上市药企研发投入Top100来了！]]></content:encoded><pubDate>Thu, 25 Feb 2021 17:56:17 +0800</pubDate></item><item><title>冲击一线失败，二线受牵连：阿斯利康撤回PD-L1单抗Imfinzi膀胱癌美国市场</title><link>https://mp.weixin.qq.com/s/9OgjyCbYW6oCR9stCZhTEw</link><description></description><content:encoded><![CDATA[冲击一线失败，二线受牵连：阿斯利康撤回PD-L1单抗Imfinzi膀胱癌美国市场]]></content:encoded><pubDate>Thu, 25 Feb 2021 17:56:17 +0800</pubDate></item><item><title>新一代肿瘤靶向药物：继ADC之后，多肽偶联药物(PDC) 已然来临</title><link>https://mp.weixin.qq.com/s/_CG7bSbaHxCihsUr5rrz8A</link><description></description><content:encoded><![CDATA[新一代肿瘤靶向药物：继ADC之后，多肽偶联药物(PDC) 已然来临]]></content:encoded><pubDate>Thu, 25 Feb 2021 17:56:17 +0800</pubDate></item><item><title>甾体龙头仙琚制药2020年度业绩快报</title><link>https://mp.weixin.qq.com/s/RG78mjtZbcsYUuofRdQpNA</link><description></description><content:encoded><![CDATA[甾体龙头仙琚制药2020年度业绩快报]]></content:encoded><pubDate>Thu, 25 Feb 2021 17:56:17 +0800</pubDate></item><item><title>眼科火热：这款新药每周费用高达3.6万</title><link>https://mp.weixin.qq.com/s/5UNdvKgmZjSx1iXbv87JEg</link><description></description><content:encoded><![CDATA[眼科火热：这款新药每周费用高达3.6万]]></content:encoded><pubDate>Wed, 24 Feb 2021 21:31:51 +0800</pubDate></item><item><title>推动细胞内各类化学反应的催化剂，“酶”有话说</title><link>https://mp.weixin.qq.com/s/Q7aFXQpOuJgIyC0KJA6rcQ</link><description></description><content:encoded><![CDATA[推动细胞内各类化学反应的催化剂，“酶”有话说]]></content:encoded><pubDate>Wed, 24 Feb 2021 21:31:51 +0800</pubDate></item><item><title>药欣生物引进凯泰资本近亿元B1轮融资</title><link>https://mp.weixin.qq.com/s/PJtF53lVegO_se3xmI83MA</link><description></description><content:encoded><![CDATA[药欣生物引进凯泰资本近亿元B1轮融资]]></content:encoded><pubDate>Wed, 24 Feb 2021 21:31:51 +0800</pubDate></item><item><title>限时免费，大湾区生物医药创新者峰会参会报名破800</title><link>https://mp.weixin.qq.com/s/75hIYoY2llbkjKl_2fWLzg</link><description></description><content:encoded><![CDATA[限时免费，大湾区生物医药创新者峰会参会报名破800]]></content:encoded><pubDate>Wed, 24 Feb 2021 21:31:51 +0800</pubDate></item><item><title>Graviton Bioscience超5亿美元获得北京泰德ROCK2抑制剂海外权益</title><link>https://mp.weixin.qq.com/s/kJVC2WZ64VjgoAssmTD2QA</link><description></description><content:encoded><![CDATA[Graviton Bioscience超5亿美元获得北京泰德ROCK2抑制剂海外权益]]></content:encoded><pubDate>Wed, 24 Feb 2021 21:31:51 +0800</pubDate></item><item><title>刚完成1.3亿美元B轮融资，Day One引进两款默克开发的MEK1/2抑制剂</title><link>https://mp.weixin.qq.com/s/dt1Q2kqthnTFe_Agkh1NCg</link><description></description><content:encoded><![CDATA[刚完成1.3亿美元B轮融资，Day One引进两款默克开发的MEK1/2抑制剂]]></content:encoded><pubDate>Wed, 24 Feb 2021 21:31:51 +0800</pubDate></item><item><title>AmacaThera完成超额认购A轮融资，开发水凝胶技术平台产品</title><link>https://mp.weixin.qq.com/s/KfHjuGPHakuu7a9kVuIJqg</link><description></description><content:encoded><![CDATA[AmacaThera完成超额认购A轮融资，开发水凝胶技术平台产品]]></content:encoded><pubDate>Wed, 24 Feb 2021 21:31:51 +0800</pubDate></item><item><title>新产业：三项生化产品取得CE准入资格</title><link>https://mp.weixin.qq.com/s/X1XNUjTL0FjTjdwRmXQ3yw</link><description></description><content:encoded><![CDATA[新产业：三项生化产品取得CE准入资格]]></content:encoded><pubDate>Wed, 24 Feb 2021 21:31:51 +0800</pubDate></item><item><title>一文初识：日本CRO产业状况及Top 6排名</title><link>https://mp.weixin.qq.com/s/aF_Z7kt3xYbYdPqXPIbsnQ</link><description></description><content:encoded><![CDATA[一文初识：日本CRO产业状况及Top 6排名]]></content:encoded><pubDate>Wed, 24 Feb 2021 08:36:34 +0800</pubDate></item><item><title>限时免费，大湾区生物医药创新者峰会参会报名破700</title><link>https://mp.weixin.qq.com/s/0BBAAMSaB4_xuQADfKBSGQ</link><description></description><content:encoded><![CDATA[限时免费，大湾区生物医药创新者峰会参会报名破700]]></content:encoded><pubDate>Wed, 24 Feb 2021 08:36:34 +0800</pubDate></item><item><title>齐鲁、信达、君实......7款新药申请上市，73个品种过评，PD-1重磅品种新适应症获批，鼻咽癌迎来“零突破”</title><link>https://mp.weixin.qq.com/s/F1YNw6ie6I-STxMeYQ0SGg</link><description></description><content:encoded><![CDATA[齐鲁、信达、君实......7款新药申请上市，73个品种过评，PD-1重磅品种新适应症获批，鼻咽癌迎来“零突破”]]></content:encoded><pubDate>Wed, 24 Feb 2021 08:36:34 +0800</pubDate></item><item><title>重磅！礼进生物完成由IDG资本领投的数亿元人民币C轮融资</title><link>https://mp.weixin.qq.com/s/zKqGWVki1s49B1cC_DhrMA</link><description></description><content:encoded><![CDATA[重磅！礼进生物完成由IDG资本领投的数亿元人民币C轮融资]]></content:encoded><pubDate>Wed, 24 Feb 2021 08:36:34 +0800</pubDate></item></channel></rss>